Common Stock, Par Value $0.001 Per Share
- Symbol
- ECOR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
electroCore, Inc.
ECORNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 6, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the first quarter ended March 31, 2026, and (ii) providing guidance for the full year of 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference.…
Company context
electroCore, Inc. and its subsidiaries are a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. For more information, visit www.electrocore.com.
Current securities
Recent company filings
- 10-Q filingNov 4, 2026
- Results of Operations and Financial ConditionNov 4, 2026
- 4 filingSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureSep 9, 2026
- 10-Q filingAug 6, 2026
Registered securities in this filing
electroCore, Inc. · 8-K · Filed 2026-05-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
May 6, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the first
quarter ended March 31, 2026, and (ii) providing guidance for the full year of 2026. A copy of the press release is furnished herewith
as Exhibit 99.1 and incorporated by reference.
The
information contained in this Item 2.02 and Item 9.01 in this Current Report on Form 8-K, including the accompanying Exhibit 99.1 hereto,
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings,
unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 electroCore Announces First Quarter 2026 Financial Results First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT ROCKAWAY, NJ, May 6, 2026 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2026. The Company reported record quarterly revenue of $9.6 million, an increase of approximately 43% year-over-year, driven by continued growth in U.S. prescription sales in the U.S. Department of Veterans Affairs (“VA”) and direct-to-consumer Truvaga sales. The Company is reaffirming its full-year 2026 revenue guidance of approximately 30% annual growth over full-year 2025. “Our first quarter results reflect what we believe is a meaningful inflection point for electroCore,” said Joshua Lev, Interim President and Chief Financial Officer of electroCore. “Quarterly…
Open exhibit ↗